CUREVAC N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.33 USD | +0.87% |
|
-4.51% | -44.66% |
| 04-26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
| 04-25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
ETFs positioned on CureVac N.V.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.74% | 17 M€ | -.--% | - | |
| 0.06% | 2 M€ | -.--% | ||
| 0.04% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.14% | - |
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Calendar
2024-05-21
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.183
EUR
Average target price
12.89
EUR
Spread / Average Target
+490.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.66% | 522M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CVAC Stock
- Funds and ETFs CureVac N.V.
